Increased risk of influenza among vaccinated adults who are obese

• Published in: International Journal of Obesity Vol. 41; no. 9; pp. 1324 - 1330
• Main Authors: Neidich, S D, Green, W D, Rebeles, J, Karlsson, E A, Schultz-Cherry, S, Noah, T L, Chakladar, S, Hudgens, M G, Weir, S S, Beck, M A
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.09.2017; Nature Publishing Group
• Subjects: 631/250; 692/308/575; 692/699/255/1578; 692/699/2743/393; 692/700/1750; 692/700/565/251/1567; 82/1; Adults; Antibodies; Anticoagulants; Body mass; Body mass index; Body weight; Complications and side effects; Criteria; Death; Development and progression; Diseases; Dosage and administration; Epidemiology; Guillain-Barre syndrome; Health aspects; Health Promotion and Disease Prevention; Illnesses; Immunomodulation; Immunosuppressive agents; Influenza; Influenza vaccines; Internal Medicine; Medical research; Medicine; Medicine & Public Health; Metabolic Diseases; Obesity; Observational studies; original-article; Public Health; Recruitment; Risk factors; Seasons; Seroconversion; Theophylline; Vaccination; Vaccine efficacy; Vaccines; Warfarin; North Carolina; Texas; California
• ISSN: 0307-0565; 1476-5497
• DOI: 10.1038/ijo.2017.131

Background: Influenza infects 5–15% of the global population each year, and obesity has been shown to be an independent risk factor for increased influenza-related complications including hospitalization and death. However, the risk of developing influenza or influenza-like illness (ILI) in a vaccinated obese adult population has not been addressed. Objective: This study evaluated whether obesity was associated with increased risk of influenza and ILI among vaccinated adults. Subjects and methods: During the 2013–2014 and 2014–2015 influenza seasons, we recruited 1042 subjects to a prospective observational study of trivalent inactivated influenza vaccine (IIV3) in adults. A total of 1022 subjects completed the study. Assessments of relative risk for laboratory confirmed influenza and ILI were determined based on body mass index. Seroconversion and seroprotection rates were determined using prevaccination and 26–35 days post vaccination serum samples. Recruitment criteria for this study were adults 18 years of age and older receiving the seasonal trivalent inactivated influenza vaccine (IIV3) for the years 2013–2014 and 2014–2015. Exclusion criteria were immunosuppressive diseases, use of immunomodulatory or immunosuppressive drugs, acute febrile illness, history of Guillain-Barre syndrome, use of theophylline preparations or use of warfarin. Results: Among obese, 9.8% had either confirmed influenza or influenza-like-illness compared with 5.1% of healthy weight participants. Compared with vaccinated healthy weight, obese participants had double the risk of developing influenza or ILI (relative risk=2.01, 95% CI 1.12, 3.60, P =0.020). Seroconversion or seroprotection rates were not different between healthy weight and obese adults with influenza or ILI. Conclusions: Despite robust serological responses, vaccinated obese adults are twice as likely to develop influenza and ILI compared with healthy weight adults. This finding challenges the current standard for correlates of protection, suggesting use of antibody titers to determine vaccine effectiveness in an obese population may provide misleading information.